Biotech with Non-Statin Cholesterol Lowering Drug Poised for Significant Catalysts in 2018

Source: John McCamant for Streetwise Reports   01/10/2018 As 2018 begins, John McCamant, editor of Medical Technology Stock Letter, reviews several 2017 top performers, discusses the turnaround at the FDA, and profiles one company with an innovative non-statin LDL cholesterol in the pipeline. 2017’s Outstanding Performance Was Led by the Four Horsemen In 2017, Medical Technology […]